News for Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development o

On May 14, 2025, Wells Fargo analyst Yanan Zhu released an update regarding Arcturus Therapeutics (ARCT), maintaining the stock's current rating at

Wells Fargo has revised its price target for Arcturus Therapeutics (ARCT), lowering it from $50 to $45, while maintaining an Overweight rating on the shares. Th

On May 13, 2025, Canaccord Genuity analyst Whitney Ijem reaffirmed a

Revenue: $29.4 million for Q1 2025, down from $38 million in Q1 2024.Research and Development Expenses: $34.9 million for Q1 2025, down from $53.6 million in Q

May 12, 2025 / 08:30PM GMTOperator Good day. I would like to welcome everyone to Arcturus's Therapeutics first quarter 2025 earnings call. (Operator Instruction

**Key Insights** Arcturus Therapeutics is making significant progress in its mRNA therapeutic programs. Analysts project a substantial upside potential f

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ETCompany ParticipantsNeda Safarzadeh - Vice...

Revenue: $29.4 million for Q1 2025, surpassing the estimated $27.88 million, but down from $38.0 million in Q1 2024 due to lower milestone revenues.Net Loss: $

Arcturus Therapeutics Holdings Inc (ARCT) is set to release its Q1 2025 earnings on May 12, 2025. The consensus estimate for Q1 2025 revenue is $27.88 million,

On Wednesday, May 7, 2025, Cathie Wood's Ark Invest Pours $24M Into Nvidia and AMD While Offloading $38.8M in Palantir Shares.

Transaction Overview On March 31, 2025, Sumitomo Mitsui Trust Group, Inc. (Trades, Portfolio) executed a strategic transaction involving Arcturus Therapeutics H

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development

Absolutely enormous things are happening all over the globe, but you aren’t hearing a lot about many of them.  That is because the mainstream media chooses to focus on stories that advance the specific narratives that they are currently pushing.  For example, virtually everyone knows who Kilmar Abrego Garcia is at this point, because the ... Read more

Arcturus Therapeutics (ARCT) has been granted fast track status by the FDA for its influenza A H5N1 vaccine, ARCT-2304. Wall Street analysts predict a s

Arcturus Therapeutics Holdings Inc. (the ”œCompany”, ”œArcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development o

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy.  In this article, we are going to take a look at where Arcturus Therapeutics Holdings Inc.

On March 14, Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the markets react to crises and what approach investors should take...

Revenue (FY 2024): $152.3 million, a decrease from $166.8 million in 2023.Revenue (Q4 2024): $22.8 million, down from $30.9 million in Q4 2023.Net Loss (FY 202